The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Mario Santinami
No Relationships to Disclose
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Mario Mandalà
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; Novartis; Roche
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Elsevier; Immunocore; Immunocore (Inst); Iovance Biotherapeutics; Merck (Inst); Novartis
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)
 
Vanna Chiarion Sileni
Consulting or Advisory Role - Merck Serono; MSD; Novartis; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Marta Nyakas
Consulting or Advisory Role - Incyte; MSD Oncology; Novartis
 
Caroline Dutriaux
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Andrew Mark Haydon
Honoraria - Merck; Novartis
Consulting or Advisory Role - Novartis; Pierre Fabre
Speakers' Bureau - Merck; Novartis
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Laurent Mortier
Honoraria - Bristol-Myers Squibb; MSD Oncology
Research Funding - MSD Oncology (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech; Roche/Genentech
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kohinoor Dasgupta
Employment - Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Monique Tan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; Incyte; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; Mologen; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Incyte; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron